Phosphodiesterase inhibitors are therapeutic agents that target PDE isoenzymes and hinder the metabolism of the secondary messengers (cyclic adenosine monophosphate, cyclic guanosine monophosphate), thereby prolonging the biological effect determined by the type of cell involved.
PDE Inhibitors Market: Introduction
- Phosphodiesterase (PDE) inhibitors are therapeutic agents that target PDE isoenzymes and hinder the metabolism of the secondary messengers (cyclic adenosine monophosphate, cyclic guanosine monophosphate), thereby prolonging the biological effect determined by the type of cell involved. Selective and non-selective PDE inhibitors are being discovered as possible treatments for various indications such as Alzheimer’s disease, chronic obstructive pulmonary disease (COPD), and other ailments. Phosphodiesterase super family is complex, large, and represents 11 gene families from phosphodiesterase 1 to phosphodiesterase 11. Each of the phosphodiesterase families contains one or four genes. The phosphodiesterase are found in plasma membranes, cytosol, nuclear membranes, endoplasmic reticulum, and cytoskeleton.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=71364
Key Drivers and Opportunities of Global PDE Inhibitors Market
- Phosphodiesterase type 5 (PDE5) inhibitors are a group of medications most commonly used to treat erectile dysfunction. PDE5 inhibitors block PDE5, an enzyme in the walls of blood vessels. Hence, rise in prevalence of erectile dysfunction is projected to boost the growth of market. Prevalence of erectile dysfunction is the highest among men with diabetes and hypertension. According to the World Health Organization, about 150 million people have been affected by erectile dysfunction across the global and the number is projected to reach 230 million by 2025. It is a common medical condition affecting about 15% of men each year.
- Increase in unmet needs in the pharmaceutical industry contribute to development of PDE inhibitor products. Hence, key players focus on investment in research & development. This in turn is anticipated to drive the global market. For instance, Adamis Pharmaceuticals Corporation announced that it has been conducting pre-IND development for tadalafil to treat erectile dysfunction.
- Strategies adopted by leading players to strengthen market position is expected to propel the global market. For instance, in September 2020, Aspargo Laboratories, Inc. acquired the international rights to Sildenafil oral spray for the treatment of erectile dysfunction.
- Governments of developing countries focus on improving health care infrastructure, and thereby increase access to pharmaceutical products. This is likely to create significant opportunities in the market.
Request for Analysis of COVID-19 Impact on PDE Inhibitors Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=71364
North America to Dominate Global PDE Inhibitors Market
- In terms of region, the global PDE inhibitors market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global PDE inhibitors market during the forecast period. Well-established health care infrastructure and presence of key players are likely to augment the market in the region.
- The PDE inhibitors market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Increase in awareness about the disease and treatment is likely to boost the growth of the market in the region.
Pre book PDE Inhibitors Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=71364<ype=S
Key Players Operating in Global PDE Inhibitors Market
The global PDE inhibitors market is fragmented due to the presence of international as well as local players. A large number of manufacturers hold major share in their respective regions.
Key players operating in the global PDE inhibitors market are:
- Metuchen Pharmaceuticals, LLC
- Viatris, Inc.
- Eli Lilly and Company
- Bayer AG
- Pfizer, Inc.
- GlaxoSmithKline
- VIVUS
- Adamis Pharmaceuticals
- Aspargo Laboratories, Inc.
- Sandoz International GmbH
- Abbott
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
Top of Form
Ask for Discount :
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=71364
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453